Does the media favor DFTX or VTRS?

In the previous week, Definium Therapeutics had 10 more articles in the media than Viatris. MarketBeat recorded 14 mentions for Definium Therapeutics and 4 mentions for Viatris. Viatris' average media sentiment score of 0.62 beat Definium Therapeutics' score of 0.18 indicating that Viatris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 3 Very Negative mention(s) Neutral Viatris 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to JAZZ or DFTX?

In the previous week, Definium Therapeutics had 3 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 14 mentions for Definium Therapeutics and 11 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 0.97 beat Definium Therapeutics' score of 0.18 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jazz Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Definium Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 3 Very Negative mention(s) Neutral

Does the media refer more to DFTX or NBIX?

In the previous week, Neurocrine Biosciences had 9 more articles in the media than Definium Therapeutics. MarketBeat recorded 23 mentions for Neurocrine Biosciences and 14 mentions for Definium Therapeutics. Neurocrine Biosciences' average media sentiment score of 1.04 beat Definium Therapeutics' score of 0.18 indicating that Neurocrine Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 3 Very Negative mention(s) Neutral Neurocrine Biosciences 12 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ELAN or DFTX?

In the previous week, Definium Therapeutics had 8 more articles in the media than Elanco Animal Health. MarketBeat recorded 14 mentions for Definium Therapeutics and 6 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 1.08 beat Definium Therapeutics' score of 0.18 indicating that Elanco Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Definium Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 3 Very Negative mention(s) Neutral

Does the media favor DFTX or CORT?

In the previous week, Definium Therapeutics had 10 more articles in the media than Corcept Therapeutics. MarketBeat recorded 14 mentions for Definium Therapeutics and 4 mentions for Corcept Therapeutics. Corcept Therapeutics' average media sentiment score of 1.73 beat Definium Therapeutics' score of 0.18 indicating that Corcept Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 3 Very Negative mention(s) Neutral Corcept Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Definium Therapeutics (DFTX) Competitors

$38.89 +1.16 (+3.07%)

As of 09/11/2026 04:00 PM Eastern

Compare

DFTX vs. VTRS, JAZZ, NBIX, ELAN, and CORT

Should you buy Definium Therapeutics stock or one of its competitors? Definium Therapeutics's main competitors and comparable companies include Viatris (VTRS), Jazz Pharmaceuticals (JAZZ), Neurocrine Biosciences (NBIX), Elanco Animal Health (ELAN), and Corcept Therapeutics (CORT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Definium Therapeutics compare to Viatris?

Definium Therapeutics (NASDAQ:DFTX) and Viatris (NASDAQ:VTRS) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

Definium Therapeutics has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A
Viatris	$14.30B	1.33	-$3.51B	-$0.36	N/A

In the previous week, Definium Therapeutics had 10 more articles in the media than Viatris. MarketBeat recorded 14 mentions for Definium Therapeutics and 4 mentions for Viatris. Viatris' average media sentiment score of 0.62 beat Definium Therapeutics' score of 0.18 indicating that Viatris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Neutral
Viatris	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Definium Therapeutics has a net margin of 0.00% compared to Viatris' net margin of -2.79%. Viatris' return on equity of 20.02% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-84.01%	-63.66%
Viatris	-2.79%	20.02%	8.02%

27.9% of Definium Therapeutics shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 2.4% of Definium Therapeutics shares are owned by insiders. Comparatively, 0.3% of Viatris shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Definium Therapeutics has a beta of 2.23, suggesting that its stock price is 123% more volatile than the broader market. Comparatively, Viatris has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market.

Definium Therapeutics presently has a consensus target price of $63.00, suggesting a potential upside of 62.00%. Viatris has a consensus target price of $18.57, suggesting a potential upside of 12.49%. Given Definium Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Definium Therapeutics is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.00
Viatris	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Definium Therapeutics beats Viatris on 10 of the 16 factors compared between the two stocks.

How does Definium Therapeutics compare to Jazz Pharmaceuticals?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Definium Therapeutics (NASDAQ:DFTX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Jazz Pharmaceuticals currently has a consensus target price of $286.72, suggesting a potential upside of 16.65%. Definium Therapeutics has a consensus target price of $63.00, suggesting a potential upside of 62.00%. Given Definium Therapeutics' higher possible upside, analysts plainly believe Definium Therapeutics is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	3.00
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.00

89.1% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 27.9% of Definium Therapeutics shares are held by institutional investors. 4.1% of Jazz Pharmaceuticals shares are held by insiders. Comparatively, 2.4% of Definium Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Definium Therapeutics had 3 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 14 mentions for Definium Therapeutics and 11 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 0.97 beat Definium Therapeutics' score of 0.18 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Definium Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Neutral

Jazz Pharmaceuticals has a net margin of 20.45% compared to Definium Therapeutics' net margin of 0.00%. Jazz Pharmaceuticals' return on equity of 33.97% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	20.45%	33.97%	13.02%
Definium Therapeutics	N/A	-84.01%	-63.66%

Jazz Pharmaceuticals has a beta of 0.36, indicating that its stock price is 64% less volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.23, indicating that its stock price is 123% more volatile than the broader market.

Definium Therapeutics has lower revenue, but higher earnings than Jazz Pharmaceuticals. Definium Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.27B	3.74	-$356.15M	$14.50	16.95
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A

Summary

Jazz Pharmaceuticals beats Definium Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Definium Therapeutics compare to Neurocrine Biosciences?

Definium Therapeutics (NASDAQ:DFTX) and Neurocrine Biosciences (NASDAQ:NBIX) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

27.9% of Definium Therapeutics shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 2.4% of Definium Therapeutics shares are held by company insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Neurocrine Biosciences has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A
Neurocrine Biosciences	$2.86B	5.55	$478.60M	$6.82	22.91

In the previous week, Neurocrine Biosciences had 9 more articles in the media than Definium Therapeutics. MarketBeat recorded 23 mentions for Neurocrine Biosciences and 14 mentions for Definium Therapeutics. Neurocrine Biosciences' average media sentiment score of 1.04 beat Definium Therapeutics' score of 0.18 indicating that Neurocrine Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Neutral
Neurocrine Biosciences	12 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neurocrine Biosciences has a net margin of 20.91% compared to Definium Therapeutics' net margin of 0.00%. Neurocrine Biosciences' return on equity of 22.43% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-84.01%	-63.66%
Neurocrine Biosciences	20.91%	22.43%	15.64%

Definium Therapeutics presently has a consensus price target of $63.00, suggesting a potential upside of 62.00%. Neurocrine Biosciences has a consensus price target of $201.09, suggesting a potential upside of 28.72%. Given Definium Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Definium Therapeutics is more favorable than Neurocrine Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.00
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.88

Definium Therapeutics has a beta of 2.23, meaning that its share price is 123% more volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

Summary

Neurocrine Biosciences beats Definium Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Definium Therapeutics compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Definium Therapeutics (NASDAQ:DFTX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Elanco Animal Health has a beta of 1.68, suggesting that its stock price is 68% more volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.23, suggesting that its stock price is 123% more volatile than the broader market.

Definium Therapeutics has lower revenue, but higher earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.46	-$232M	-$0.41	N/A
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A

97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 27.9% of Definium Therapeutics shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by company insiders. Comparatively, 2.4% of Definium Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Definium Therapeutics had 8 more articles in the media than Elanco Animal Health. MarketBeat recorded 14 mentions for Definium Therapeutics and 6 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 1.08 beat Definium Therapeutics' score of 0.18 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Definium Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Neutral

Definium Therapeutics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -3.96%. Elanco Animal Health's return on equity of 8.13% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-3.96%	8.13%	3.99%
Definium Therapeutics	N/A	-84.01%	-63.66%

Elanco Animal Health presently has a consensus price target of $29.09, suggesting a potential upside of 25.42%. Definium Therapeutics has a consensus price target of $63.00, suggesting a potential upside of 62.00%. Given Definium Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Definium Therapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Definium Therapeutics beats Elanco Animal Health on 10 of the 16 factors compared between the two stocks.

How does Definium Therapeutics compare to Corcept Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and Corcept Therapeutics (NASDAQ:CORT) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

In the previous week, Definium Therapeutics had 10 more articles in the media than Corcept Therapeutics. MarketBeat recorded 14 mentions for Definium Therapeutics and 4 mentions for Corcept Therapeutics. Corcept Therapeutics' average media sentiment score of 1.73 beat Definium Therapeutics' score of 0.18 indicating that Corcept Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Neutral
Corcept Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Definium Therapeutics has a beta of 2.23, suggesting that its share price is 123% more volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market.

Definium Therapeutics presently has a consensus target price of $63.00, indicating a potential upside of 62.00%. Corcept Therapeutics has a consensus target price of $138.17, indicating a potential upside of 22.50%. Given Definium Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Definium Therapeutics is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.00
Corcept Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Corcept Therapeutics has a net margin of 6.52% compared to Definium Therapeutics' net margin of 0.00%. Corcept Therapeutics' return on equity of 8.26% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-84.01%	-63.66%
Corcept Therapeutics	6.52%	8.26%	6.45%

Corcept Therapeutics has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A
Corcept Therapeutics	$761.41M	16.01	$99.65M	$0.42	268.55

27.9% of Definium Therapeutics shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 2.4% of Definium Therapeutics shares are held by company insiders. Comparatively, 20.7% of Corcept Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Corcept Therapeutics beats Definium Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Definium Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DFTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DFTX vs. The Competition

Export

Metric	Definium Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.23B	$12.41B	$7.16B	$12.85B
Dividend Yield	N/A	2.64%	2.57%	11.71%
P/E Ratio	-11.34	799.75	274.94	25.33
Price / Sales	N/A	756.96	633.80	90.72
Price / Cash	N/A	14.86	28.42	34.96
Price / Book	11.57	10.39	10.33	6.21
Net Income	-$183.79M	$2.85B	$3.50B	$358.54M
7 Day Performance	2.10%	-3.61%	-3.32%	-2.35%
1 Month Performance	-11.41%	0.72%	-0.53%	-3.23%
1 Year Performance	311.97%	3.61%	23.51%	8.79%

Definium Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DFTX Definium Therapeutics	2.9711 of 5 stars	$38.89 +3.1%	$63.00 +62.0%	+312.0%	$5.23B	N/A	N/A	40	News Coverage Analyst Forecast
VTRS Viatris	2.4653 of 5 stars	$16.88 flat	$17.50 +3.7%	+65.8%	$19.39B	$14.30B	N/A	30,000	News Coverage Analyst Forecast
JAZZ Jazz Pharmaceuticals	4.4118 of 5 stars	$246.81 flat	$285.44 +15.7%	+94.8%	$16.02B	$4.27B	17.02	2,890	News Coverage Analyst Forecast Insider Trade Gap Down
NBIX Neurocrine Biosciences	4.8443 of 5 stars	$155.64 flat	$201.05 +29.2%	+10.1%	$15.82B	$2.86B	22.82	2,000	Positive News Analyst Forecast
ELAN Elanco Animal Health	4.7534 of 5 stars	$24.48 -0.1%	$29.09 +18.8%	+25.3%	$12.24B	$4.72B	N/A	9,400	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DFTX) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Definium Therapeutics (DFTX) Competitors

DFTX vs. VTRS, JAZZ, NBIX, ELAN, and CORT

How does Definium Therapeutics compare to Viatris?

Summary

How does Definium Therapeutics compare to Jazz Pharmaceuticals?

Summary

How does Definium Therapeutics compare to Neurocrine Biosciences?

Summary

How does Definium Therapeutics compare to Elanco Animal Health?

Summary

How does Definium Therapeutics compare to Corcept Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DFTX vs. The Competition

Definium Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Definium Therapeutics (DFTX) Competitors

DFTX vs. VTRS, JAZZ, NBIX, ELAN, and CORT

How does Definium Therapeutics compare to Viatris?

Which has higher valuation & earnings, DFTX or VTRS?

Does the media favor DFTX or VTRS?

Is DFTX or VTRS more profitable?

Do institutionals and insiders have more ownership in DFTX or VTRS?

Which has more risk & volatility, DFTX or VTRS?

Do analysts prefer DFTX or VTRS?

Summary

How does Definium Therapeutics compare to Jazz Pharmaceuticals?

Do analysts recommend JAZZ or DFTX?

Do insiders & institutionals have more ownership in JAZZ or DFTX?

Does the media refer more to JAZZ or DFTX?

Is JAZZ or DFTX more profitable?

Which has more risk & volatility, JAZZ or DFTX?

Which has better valuation & earnings, JAZZ or DFTX?

Summary

How does Definium Therapeutics compare to Neurocrine Biosciences?

Do insiders & institutionals hold more shares of DFTX or NBIX?

Which has higher valuation & earnings, DFTX or NBIX?

Does the media refer more to DFTX or NBIX?

Is DFTX or NBIX more profitable?

Do analysts recommend DFTX or NBIX?

Which has more risk & volatility, DFTX or NBIX?

Summary

How does Definium Therapeutics compare to Elanco Animal Health?

Which has more risk and volatility, ELAN or DFTX?

Which has better earnings and valuation, ELAN or DFTX?

Do insiders and institutionals have more ownership in ELAN or DFTX?

Does the media prefer ELAN or DFTX?

Is ELAN or DFTX more profitable?

Do analysts recommend ELAN or DFTX?

Summary

How does Definium Therapeutics compare to Corcept Therapeutics?

Does the media favor DFTX or CORT?

Which has more risk & volatility, DFTX or CORT?

Do analysts recommend DFTX or CORT?

Is DFTX or CORT more profitable?

Which has preferable earnings and valuation, DFTX or CORT?

Do insiders & institutionals believe in DFTX or CORT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DFTX vs. The Competition

Definium Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools